KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2021 - 2025)

Alnylam Pharmaceuticals' Long-Term Debt Issuances history spans 3 years, with the latest figure at -$680000.0 for Q4 2025.

  • For Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$680000.0; the TTM value through Dec 2025 reached -$1.5 million, down 100.14%, while the annual FY2025 figure was $645.7 million, N/A changed from the prior year.
  • Long-Term Debt Issuances reached -$680000.0 in Q4 2025 per ALNY's latest filing, up from -$777000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $1.0 billion in Q3 2022 to a low of -$250.0 million in Q3 2021.
  • Average Long-Term Debt Issuances over 3 years is $191.4 million, with a median of -$728500.0 recorded in 2022.
  • The largest YoY upside for Long-Term Debt Issuances was 506.76% in 2022 against a maximum downside of 506.76% in 2022.
  • A 3-year view of Long-Term Debt Issuances shows it stood at -$250.0 million in 2021, then skyrocketed by 99.69% to -$777000.0 in 2022, then increased by 12.48% to -$680000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Long-Term Debt Issuances are -$680000.0 (Q4 2025), -$777000.0 (Q4 2022), and $1.0 billion (Q3 2022).